ImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035

ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a vertically integrated commercial-stage immunotherapy company, today announced that five United States patents